Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semenchuk, M. R.
Right arrow Articles by Davis, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semenchuk, M. R.
Right arrow Articles by Davis, B.
Related Collections
Right arrow Peripheral neuropathy
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Neuropathic pain
Neurology 2001;57:1583-1588
© 2001 American Academy of Neurology


Articles

Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

Marilyn R. Semenchuk, PharmD, Scott Sherman, MD and Bennet Davis, MD

From the Department of Neurology (Drs. Semenchuk and Sherman) and the Pain Clinic (Dr. Davis), University of Arizona, Tucson.

Address correspondence and reprint requests to Dr. Semenchuk, 9030 North Silvermoon Way, Tucson, AZ 85743; e-mail: Marilyn.R.Semenchuk{at}gsk.com

Objective:— To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain.

Method:— This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondepressed patients with neuropathic pain spent 6 weeks in each phase in random order and received identical tablets of 150 mg bupropion SR or placebo. Patients were instructed to take one tablet once daily for 1 week followed by one tablet twice daily for 5 weeks.

Results:— While the patients took bupropion SR, neuropathic pain relief was improved or much improved in 30 (73%) patients, and one of these patients became pain-free. The mean average pain score at baseline was 5.7, which remained unchanged at the end of week 6 with placebo, but decreased by 1.7 points to 4.0 (p < 0.001) during therapy with bupropion SR. Pain relief with bupropion SR was significant at week 2 (p < 0.05) and continued throughout weeks 3 through 6 (p < 0.001). A significant decrease in interference of pain on quality of life was observed while patients were receiving bupropion SR compared with placebo. Side effects experienced with bupropion SR were not dose-limiting and consisted primarily of dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness.

Conclusion:— This placebo-controlled crossover trial showed that bupropion SR (150–300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. A. Krieter, M. Gohdes, T. J. Musick, F. P. Duncanson, and W. E. Bridson
Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans
Drug Metab. Dispos., February 1, 2008; 36(2): 252 - 259.
[Abstract] [Full Text] [PDF]


Home page
DOC NewsHome page
K. Ullman
Diabetes and Depression Combo Poses Management Challenge
DOC News, June 1, 2007; 4(6): 1 - 21.
[Full Text]


Home page
FocusHome page
J. M. Lyness
End-of-Life Care: Issues Relevant to the Geriatric Psychiatrist
Focus, January 1, 2007; 5(4): 459 - 471.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean
Consensus Guidelines: Treatment Planning and Options
Mayo Clin. Proc., April 1, 2006; 81(4_Suppl): S12 - S25.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
E. Fink and A. L. Oaklander
Small-fiber neuropathy: answering the burning questions.
Sci. Aging Knowl. Environ., February 15, 2006; 2006(6): pe7 - pe7.
[Abstract] [Full Text]


Home page
NeurologyHome page
G. A. Irving
Contemporary assessment and management of neuropathic pain
Neurology, June 28, 2005; 64(12_suppl_3): S21 - S27.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
J. M. Lyness
End-of-Life Care: Issues Relevant to the Geriatric Psychiatrist
Focus, April 1, 2005; 3(2): 341 - 353.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
K. Scott and M. J. Kothari
Evaluating the Patient with Peripheral Nervous System Complaints
J Am Osteopath Assoc, February 1, 2005; 105(2): 71 - 83.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
H. Chen, T. J. Lamer, R. H. Rho, K. A. Marshall, B. T. Sitzman, S. M. Ghazi, and R. P. Brewer
Contemporary Management of Neuropathic Pain for the Primary Care Physician
Mayo Clin. Proc., December 1, 2004; 79(12): 1533 - 1545.
[Abstract] [PDF]


Home page
The OncologistHome page
D. Lussier, A. G. Huskey, and R. K. Portenoy
Adjuvant Analgesics in Cancer Pain Management
Oncologist, September 1, 2004; 9(5): 571 - 591.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. A. Amato and A. L. Oaklander
Case 16-2004 - A 76-Year-Old Woman with Numbness and Pain in the Feet and Legs
N. Engl. J. Med., May 20, 2004; 350(21): 2181 - 2189.
[Full Text] [PDF]


Home page
Arch NeurolHome page
R. H. Dworkin, M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, et al.
Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations
Arch Neurol, November 1, 2003; 60(11): 1524 - 1534.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
E. Rock and A. DeMichele
Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors
J. Nutr., November 1, 2003; 133(11): 3785S - 3793.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. R. Mendell and Z. Sahenk
Painful Sensory Neuropathy
N. Engl. J. Med., March 27, 2003; 348(13): 1243 - 1255.
[Full Text] [PDF]


Home page
JWatch GastroenterologyHome page
Sustained-Release Bupropion for Neuropathic Pain
Journal Watch Gastroenterology, February 13, 2002; 2002(213): 11 - 11.
[Full Text]


Home page
JWatch PsychiatryHome page
Bupropion Eases Neuropathic Pain
Journal Watch Psychiatry, December 20, 2001; 2001(1220): 5 - 5.
[Full Text]


Home page
JWatch GeneralHome page
Sustained-Release Bupropion for Neuropathic Pain
Journal Watch (General), December 14, 2001; 2001(1214): 2 - 2.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.